Reunion Neuroscience Inc. today announced positive topline results from its RECONNECT Phase 2 clinical trial evaluating RE104 in adult female patients with moderate-to-severe postpartum depression (PPD). ...
Reunion Neuroscience Inc. today announced the publication of a manuscript entitled “Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous RE104: A Double-Blind, Randomized, Single Ascending Dose Placebo-Controlled Study,” describing the results of a Phase 1 study of RE104 in the peer-reviewed Journal of Clinical Psychopharmacology....
Reunion Neuroscience, Inc. today announced the completion of patient enrollment and the last patient dosed in RECONNECT, a Phase 2 clinical trial evaluating RE104 in adult female patients with moderate-to-severe postpartum depression (PPD). ...
Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic-inspired therapeutic solutions, presented the study design for the REKINDLE Phase 2 clinical trial, which will evaluate the safety and efficacy of RE104 for the treatment of adjustment...
Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic-inspired therapeutic solutions, today announced its participation in The Policy Center for Maternal Mental Health’s 2025 Maternal Mental Health (MMH) FORUM, taking place March 18-19, 2025....
Reunion Neuroscience Inc. today announced program updates and anticipated 2025 milestones. The Company also announced that Greg Mayes, President and Chief Executive Officer, will present a corporate overview and participate in a panel discussion entitled “Future of Psychedelics” at the 8th Annual Neuroscience Innovation Forum, taking place January 12, 2025...
Reunion Neuroscience Inc. presented a poster detailing RE104 Phase 1 data at the American College of Neuropsychopharmacology (ACNP) 63rd Annual Meeting in Phoenix, Arizona. ...
Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic therapeutic solutions, today announced a new partnership with the Seleni Institute, a New York City based nonprofit that provides treatment and training regarding maternal mental health and...
Reunion Neuroscience Inc. today announced the appointment of Mark Pollack, M.D., as Chief Medical Officer. Dr. Pollack previously served as a member of Reunion’s Advisory Board and is a highly accomplished psychiatrist with decades of leadership experience in neuroscience-focused drug development and clinical research. Pollack replaces Dr. Robert Alexander who...
Reunion Neuroscience Inc. today announced its sponsorship of “Is Mom Ok?” in recognition of Maternal Suicide Prevention Month. This unprecedented initiative, launched by Cherished Mom, a renowned nonprofit organization dedicated to transforming the landscape of maternal mental health, is aimed at providing essential support and resources for pregnant and postpartum...